17.05.2010 • NewsAstellasOSIMergers & Acquisitions (M&A)

Astellas CEO Says Seeks to Buy 90% Of OSI Shares

Astellas Pharma, Japan's No.2 drugmaker, seeks to buy at least 90% of shares in U.S. drugmaker OSI Pharmaceuticals with its tender offer, the company's chief executive said on Monday.

"As for how many shares we may obtain, we will carry out the tender offer, targeting 90% or more," Astellas president Masafumi Nogimori told a news conference.

Astellas, Japan's No.2 drugmaker, agreed to buy the U.S. biotech for $4 billion in cash in a sweetened bid that allows it to add OSI's blockbuster cancer drug Tarceva to its line-up.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.